国泰中证沪港深创新药产业ETF(517110)利润分配表
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 收入 |
63,776,860.02 |
-28,281,116.87 |
-50,504,830.04 |
-23,869,081.27 |
| 利息合计 |
8,541.57 |
17,391.03 |
7,032.11 |
30,045.83 |
| 其中：存款利息收入 |
8,541.57 |
17,391.03 |
7,032.11 |
30,045.83 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
3,961,703.93 |
-17,513,998.22 |
-11,503,382.88 |
-15,736,562.50 |
| 其中：股票投资收益 |
2,376,274.04 |
-19,606,429.16 |
-12,780,173.92 |
-17,242,765.20 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
1,585,429.89 |
2,092,430.94 |
1,276,791.04 |
1,506,202.70 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
59,622,041.57 |
-11,122,852.64 |
-39,137,663.28 |
-8,320,280.88 |
| 其他收入 |
184,572.95 |
338,342.96 |
129,184.01 |
157,716.28 |
| 费用 |
870,034.08 |
1,157,043.72 |
528,203.72 |
1,141,992.77 |
| 管理人报酬 |
654,648.50 |
832,078.60 |
369,764.63 |
809,966.27 |
| 基金托管费 |
130,929.71 |
166,415.73 |
73,952.99 |
161,993.25 |
| 销售服务费 |
- |
- |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
84,455.87 |
158,549.39 |
84,486.10 |
170,033.25 |
| 利润总额 |
62,906,825.94 |
-29,438,160.59 |
-51,033,033.76 |
-25,011,074.04 |
微信公众号
证券之星APP
基本资料
